Work

Supplemental Figure 1 from Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC

Year: 2023

Type: supplementary-materials

Abstract: Time From First Dose of Immunotherapy to Date of The Initial irAE

DOI: 10.1158/2326-6066.22539406

Authors: Fernando C. Santini, Hira Rizvi, Andrew J. Plodkowski, Andy Ni, Mario E. Lacouture, Maya Gambarin-Gelwan, Olivia Wilkins, Elizabeth Panora, Darragh F. Halpenny, Niamh M. Long, Mark G. Kris, Charles M. Rudin, Jamie E. Chaft, Matthew D. Hellmann

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4362618842

Cites:

Cited by:

Related to: 10